Skip to main content

Table 1 Characteristics of randomised controlled trials comparing acyclovir to placebo among immunocompetent children

From: Acyclovir for treating varicella in otherwise healthy children and adolescents: a systematic review of randomised controlled trials

Study Number of participants Age Range (mean) Acyclovir protocol Outcomes Quality
  Total Per group     Jadad Score Allocation Concealment
Balfour 1990 102 50 – acyclovir
50 – placebo
5–16 years (8.1) 5–7 years: 20 mg/kg
7–12 years: 15 mg/kg
12–16 years: 10 mg/kg
4x/days for 5-7 days
• Days to fever, crusting, no
new lesions, maximum number
of lesions, decrease in number
of lesions and cessation of
itching
• Maximum number of lesions
4 Unclear
Dunkle 1991 815 408 – acyclovir
407 – placebo
2–12 years (5.2) 20 mg/kg 4×/day for 5 days • Maximum number of lesions
• Number with >500 lesions
• Residual lesions at day 28
3 Unclear
Balfour 1992 62 31 – acyclovir
31 – placebo
13–18 years (14.8) 800 mg 4×/day for 5 days • Days to maximum number of
lesions and cessation of
itching
• Maximum number of lesions
• Residual lesions at day 28
3 Unclear